Gapping up
In reaction to strong earnings/guidance: NHTC +23.7%, ( increases dividend by 33% to $0.04 per share, authorizes $15 mln share repurchase) STLY +19.8%, RUBI +16.5%, CALX +14.3%, AIZ +9.6%, MTSI +8.6%, BBSI +8.5%, BWLD +8%, PNRA +7.8%, RSYS +7.4%, MVIS +7.4%, CLF +7.1%, VIV +6.5%, ATRC +5.9%, FCF +5.5%, WNC +5.1%, NVMI +4.9%, CETV+4.4%, SONS +4.4%, BLDP +4.3%, NUVA +4.1%, (reached a definitive settlement with the US DOJ; co will pay $13.5 mln, plus fees and accrued interest in settlement ), CTXS +3.8%, (Citrix Systems enters into an agreement with Elliott Management Corporation; appoints Elliott's Jesse Cohn to the Board; announces the impending retirement of CEO Mark Templeton; co initiates a CEO search process ), GILD +3.7%, MILL +3.6%, WOOF +3.3%, ACCO +3.1%, AMED +3%, RGR +2.9%, TRU +2.6%, ANTM +2.5%, X +2.4%, GD +2.2%, STRZA +2.2%, BCS +2.1%, STNG +2.1%, MNDO +2.1%, IP +2%, NGD +1.9%, IACI +1.7%, HLT +1.5%, HURN +1.3%, MO +1.2%, NCR +1%, CRI +1%, APC +0.9%, PAG +0.9%
M&A news: CYT +27.6% (Solvay (SVYZY) to acquire Cytec for $75.25 per share in cash)
Other news: NHTC +23.4% (increased quarterly dividend by 33% and authorized $15 mln share repurchase; co also reported earnings), OGEN +19% (announced positive data for multiple compounds from its Mutacin 1140 lantibiotic platform ), MNGA +7% (announces that a major waste to energy company has placed multiple orders), GALE +5.6% (announced the product launch for Zuplenz (ondansetron) Oral Soluble Film in the United States), ARNA +4.9% (initiates a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis), ARIA +2.2% (PDL BioPharma enters into a revenue interest assignment agreement, to provide ARIAD Pharmaceuticals (ARIA) with up to $200 million in financing, in exchange for royalties on Iclusig), STO +1.5% (cont strength)
Analyst comments: SALT +4.5% (upgraded to Buy from Hold at Deutsche Bank), AKS +3.8% (upgraded to Outperform from Neutral at Macquarie ), YRCW +3.6% (upgraded to Strong Buy from Mkt Perform at Raymond James), DDD +2% (upgraded to Neutral from Underperform at Longbow), AMZN +1% (upgraded to Buy from Hold at Stifel), WFC +0.5% (upgraded to Buy from Neutral at Guggenheim
)
In reaction to strong earnings/guidance: NHTC +23.7%, ( increases dividend by 33% to $0.04 per share, authorizes $15 mln share repurchase) STLY +19.8%, RUBI +16.5%, CALX +14.3%, AIZ +9.6%, MTSI +8.6%, BBSI +8.5%, BWLD +8%, PNRA +7.8%, RSYS +7.4%, MVIS +7.4%, CLF +7.1%, VIV +6.5%, ATRC +5.9%, FCF +5.5%, WNC +5.1%, NVMI +4.9%, CETV+4.4%, SONS +4.4%, BLDP +4.3%, NUVA +4.1%, (reached a definitive settlement with the US DOJ; co will pay $13.5 mln, plus fees and accrued interest in settlement ), CTXS +3.8%, (Citrix Systems enters into an agreement with Elliott Management Corporation; appoints Elliott's Jesse Cohn to the Board; announces the impending retirement of CEO Mark Templeton; co initiates a CEO search process ), GILD +3.7%, MILL +3.6%, WOOF +3.3%, ACCO +3.1%, AMED +3%, RGR +2.9%, TRU +2.6%, ANTM +2.5%, X +2.4%, GD +2.2%, STRZA +2.2%, BCS +2.1%, STNG +2.1%, MNDO +2.1%, IP +2%, NGD +1.9%, IACI +1.7%, HLT +1.5%, HURN +1.3%, MO +1.2%, NCR +1%, CRI +1%, APC +0.9%, PAG +0.9%
M&A news: CYT +27.6% (Solvay (SVYZY) to acquire Cytec for $75.25 per share in cash)
Other news: NHTC +23.4% (increased quarterly dividend by 33% and authorized $15 mln share repurchase; co also reported earnings), OGEN +19% (announced positive data for multiple compounds from its Mutacin 1140 lantibiotic platform ), MNGA +7% (announces that a major waste to energy company has placed multiple orders), GALE +5.6% (announced the product launch for Zuplenz (ondansetron) Oral Soluble Film in the United States), ARNA +4.9% (initiates a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis), ARIA +2.2% (PDL BioPharma enters into a revenue interest assignment agreement, to provide ARIAD Pharmaceuticals (ARIA) with up to $200 million in financing, in exchange for royalties on Iclusig), STO +1.5% (cont strength)
Analyst comments: SALT +4.5% (upgraded to Buy from Hold at Deutsche Bank), AKS +3.8% (upgraded to Outperform from Neutral at Macquarie ), YRCW +3.6% (upgraded to Strong Buy from Mkt Perform at Raymond James), DDD +2% (upgraded to Neutral from Underperform at Longbow), AMZN +1% (upgraded to Buy from Hold at Stifel), WFC +0.5% (upgraded to Buy from Neutral at Guggenheim
)